CRISPR 3.0 Emerges

Base editing and prime editing now surpass original CRISPR-Cas9 precision. These tools alter single DNA letters without cutting both strands, reducing unintended mutations. Recent trials show promise for sickle cell disease, with potential cures requiring no bone marrow transplants. The technology evolves monthly; regulatory frameworks struggle to keep pace. Ethical debates intensify as germline editing—heritable genetic changes—becomes technically feasible, forcing society to define where therapy ends and enhancement begins.